07:02 AM EDT, 08/05/2026 (MT Newswires) -- Berenberg revised its estimates for Haleon (HLN.L) as analysts took note of the company's first-half performance in a Wednesday research report. For the six months ended June 30, the British consumer healthcare company reported revenue of 5.60 billion pounds sterling, up 2.2% year over year, while gross profit rose 4.7% to 3.69 billion pounds. "While performance was impeded by a weak cold and flu season and softer European consumption, we note investments in North America, China and Latin America are starting to bear fruit. We believe improved agility and execution are reflected in the step up in market share gained/maintained in H126 to 73% (60% in FY25)," analysts said. Against this backdrop, the research firm lifted its EBIT and EPS estimates for 2026 through 2028. On the flip side, sales forecasts were trimmed across the three-year period, with analysts also noting the company's latest management commentary and foreign exchange rates. The stock's buy rating was kept, while its price target was increased to 5.14 pounds sterling from 5.12 pounds.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.